Evidence map›Paper›PMID 25070717›Full record

ArticleBiomacromolecules2014

Impact of hydrophobic chain composition on amphiphilic macromolecule antiatherogenic bioactivity.

Allison Faig, Latrisha K Petersen, Prabhas V Moghe, Kathryn E Uhrich

Open access · greenAbstract read
In one paragraph

Article in Biomacromolecules, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Allison FaigDepartment of Chemistry and Chemical Biology, ‡Department of Biomedical Engineering, and §Department of Chemical and Biochemical Engineering, Rutgers University , Piscataway, New Jersey 08854, United States.
Latrisha K Petersen
Prabhas V Moghe
Kathryn E Uhrich
Rutgers, The State University of New Jersey · US

Funding

Synthetic Counter-ligands for Inhibition of AtherosclerosisR01HL107913 · NHLBI · RUTGERS, THE STATE UNIV OF N.J. · PI MOGHE, PRABHAS V, UHRICH, KATHRYN ELIZABETH · 2011 to 2014
$2.3M
NHLBI NIH HHS R01 HL107913
6 · The paper itself

Abstract

Amphiphilic macromolecules (AMs) composed of sugar backbones modified with branched aliphatic chains and a poly(ethylene glycol) (PEG) tail can inhibit macrophage uptake of oxidized low-density lipoproteins (oxLDL), a major event underlying atherosclerosis development. Previous studies indicate that AM hydrophobic domains influence this bioactivity through interacting with macrophage scavenger receptors, which can contain basic and/or hydrophobic residues within their binding pockets. In this study, we compare two classes of AMs to investigate their ability to promote athero-protective potency via hydrogen-bonding or hydrophobic interactions with scavenger receptors. A series of ether-AMs, containing methoxy-terminated aliphatic arms capable of hydrogen-bonding, was synthesized. Compared to analogous AMs containing no ether moieties (alkyl-AMs), ether-AMs showed improved cytotoxicity profiles. Increasing AM hydrophobicity via incorporation of longer and/or alkyl-terminated hydrophobic chains yielded macromolecules with enhanced oxLDL uptake inhibition. These findings indicate that hydrophobic interactions and the length of AM aliphatic arms more significantly influence AM bioactivity than hydrogen-bonding.

Indexed as

Lipoproteins, LDLPolyethylene GlycolsReceptors, ScavengerAtherosclerosisFemaleHumansHydrophobic and Hydrophilic InteractionsMaleMonocytesLipoproteins, LDLoxidized low density lipoproteinPolyethylene GlycolsReceptors, Scavenger

Identifiers

PMID25070717
PMCPMC4157764
OpenAlexW2334480013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.